Freakonomics Radio

In a wide-ranging conversation with Ezekiel Emanuel, the policymaking physician and medical gadfly, we discuss the massive effects of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. We also talk about the state of cancer care, mysteries in the gut microbiome, flaws in the U.S. healthcare system — and what a second Trump term means for healthcare policy. SOURCES:Ezekiel Emanuel, vice provost for Global Initiatives, co-director of the Health Transformation Institute, and professor at the University of Pennsylvania Perelman School of Medicine. RESOURCES:"Obesity Drugs Would Be Covered by Medicare and Medicaid Under Biden Proposal," by Margot Sanger-Katz (The New York Times, 2024)."International Coverage of GLP-1 Receptor Agonists: A Review and Ethical Analysis of Discordant Approaches," by Johan L. Dellgren, and Govind Persad, and Ezekiel J. Emanuel (The Lancet, 2024).The Coming Wave: Technology, Power, and the Twenty-first Century's Greatest Dilemma, by Mustafa Suleyman (2023)."The Significance of Blockbusters